Abbott (NYSE:ABT) announced today that the FDA approved its spinal cord stimulation system for treating painful diabetic peripheral neuropathy (DPN). The Proclaim XR SCS system offers relief to patients with DPN, a debilitating complication of diabetes. These patients need alternatives to traditional treatment approaches like oral medication. Users of Proclaim XR can also use Abbott’s […]
Pain Management
Avanos Medical fills two new C-level posts
Avanos Medical (NYSE:AVNS) today announced appointments to two new C-level positions on its leadership team. The company’s present SVP CFO Michael Greiner will also fill a chief transformation officer role. In addition, Avanos promoted Kerr Holbrook to SVP and chief commercial officer. Alpharetta, Georgia–based Avanos Medical is a developer of medtech that provides everything from […]
Nevro announces CEO succession plan, preliminary Q4 results
Nevro (NYSE:NVRO) today announced that Chair, CEO and President D. Keith Grossman intends to retire this year. Grossman informed the board that he plans to retire from his CEO and president duties in 2023. He intends to do so following the selection of his successor at the spinal cord stimulation (SCS) technology developer. Following the […]
FDA approves implantable rechargeable spinal cord stimulation system from Abbott
Abbott (NYSE:ABT) announced today that the FDA approved its Eterna spinal cord stimulation (SCS) system. Eterna is an implantable, rechargeable SCS system. It offers treatment for chronic pain. Abbott said in a news release that Eterna represents the smallest such SCS system on the market for that indication. The system uses Abbott’s proprietary low-dose BurstDR […]
NeuroOne begins shipping 30-day sEEG electrodes to Zimmer Biomet
NeuroOne Medical Technologies (Nasdaq:NMTC) announced today that shipped its first commercial order in an agreement with Zimmer Biomet (NYSE:ZBH). Zimmer Biomet holds an exclusive development and distribution agreement with NeuroOne for its thin film technology. It already sells NeuroOne’s earlier cortical strip and grid electrode devices. Over a year ago, Zimmer Biomet placed initial stocking […]
Avanos Medical rises on mixed bag Q3
Avanos Medical (NYSE:AVNS) shares rose this morning on third-quarter results that beat the consensus forecast. Shares of AVNS ticked up 3.5% at $23.20 apiece. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — ticked up by 1%. The Alpharetta, Georgia-based pain management and chronic care company posted profits […]
FDA approves Nevro HFX iQ spinal cord stimulation
Nevro (NYSE:NVR) announced that the FDA approved its Senza HFX iQ spinal cord stimulation (SCS) system. Redwood City, California-based Nevro designed Senza HFX iQ to use artificial intelligence (AI) to learn from patients. The company says it’s the first such SCS system. It utilizes Nevro’s high-frequency 10 kHz therapy platform. The company developed it to […]
Nevro wins FDA approval for manufacturing operations in Costa Rica
Nevro (NYSE:NVRO) announced that the FDA approved manufacturing operations in Costa Rica for the production of its spinal cord stimulation (SCS) systems. Redwood City, Californa-based Nevro’s new facility sits in the Coyol Free Trade Zone in Alajuela, Costa Rica. It produces proprietary SCS systems that treat chronic pain, including the HFX product platform. The facility […]
Nevro wins multiple coverage options for spinal cord stimulation
Nevro (NYSE:NVRO) today announced positive updates to multiple spinal cord stimulation (SCS) coverage policies. Aetna’s new SCS policy explicitly covers PDN (painful diabetic neuropathy), effective Aug. 29, 2022. Aetna’s health plan covers approximately 22 million commercial lives. Novitas and First Coast, Medicare Administrative Contractors (MACs) that represent 12 states, also provided a positive update. They […]
FDA approves Abbott’s next-gen spinal cord stimulation therapy
Abbott (NYSE:ABT) announced today that the FDA approved its new Proclaim Plus spinal cord stimulation (SCS) system with FlexBurst360. The FlexBurst360 therapy is the next generation of Abbott’s proprietary BurstDR stimulation. Abbott designed it to provide pain coverage across up to six areas of the trunk and/or limbs. It has programming that adjusts as a […]
Zimmer Biomet speeds up investments in NeuroOne
NeuroOne Medical Technologies (Nasdaq: NMTC) announced today that it will receive an accelerated $3.5 million milestone payment from Zimmer Biomet. The milestone payment is related to Eden Prairie, Minnesota–based NeuroOne’s Evo sEEG electrode technology, which last year received FDA 510(k) clearance for temporary (less than 24 hours) recording, monitoring and stimulation of electrical signals at […]